Mitoxantrone-d8

• UNSPSC Description:

  Mitoxantrone-d8 (mitozantrone-d8) is the deuterium labeled Mitoxantrone. Mitoxantrone is a topoisomerase II inhibitor and also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM[1][2].

• Target Antigen:

  Isotope-Labeled Compounds; PKC; Topoisomerase

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics;Others;TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  N(CCNC(C(O)([2H])[2H])([2H])[2H])C1=C2C(=C(NCCNC(C(O)([2H])[2H])([2H])[2H])C=C1)C(=O)C=3C(C2=O)=C(O)C=CC3O

• Molecular Weight:

  452.53

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7.|[3]Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.|[4]Vibet S, et al. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007 May;35(5):822-8.|[5]Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1189974-82-0